BR112023002662A2 - Compostos de heteroarila substituída úteis como inibidores de tlr9 - Google Patents
Compostos de heteroarila substituída úteis como inibidores de tlr9Info
- Publication number
- BR112023002662A2 BR112023002662A2 BR112023002662A BR112023002662A BR112023002662A2 BR 112023002662 A2 BR112023002662 A2 BR 112023002662A2 BR 112023002662 A BR112023002662 A BR 112023002662A BR 112023002662 A BR112023002662 A BR 112023002662A BR 112023002662 A2 BR112023002662 A2 BR 112023002662A2
- Authority
- BR
- Brazil
- Prior art keywords
- substituted heteroaryl
- compounds
- compounds useful
- heteroaryl compounds
- tlr9 inhibitors
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 title abstract 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063067389P | 2020-08-19 | 2020-08-19 | |
| PCT/US2021/046475 WO2022040293A1 (en) | 2020-08-19 | 2021-08-18 | Substituted heteroaryl compounds useful as inhibitors of tlr9 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023002662A2 true BR112023002662A2 (pt) | 2023-03-14 |
Family
ID=77726550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023002662A BR112023002662A2 (pt) | 2020-08-19 | 2021-08-18 | Compostos de heteroarila substituída úteis como inibidores de tlr9 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230322770A1 (https=) |
| EP (1) | EP4200015B1 (https=) |
| JP (1) | JP2023539136A (https=) |
| KR (1) | KR20230052930A (https=) |
| CN (1) | CN115956077A (https=) |
| AR (1) | AR123284A1 (https=) |
| AU (1) | AU2021328362A1 (https=) |
| BR (1) | BR112023002662A2 (https=) |
| CA (1) | CA3189816A1 (https=) |
| CL (1) | CL2023000428A1 (https=) |
| CO (1) | CO2023001670A2 (https=) |
| IL (1) | IL300696A (https=) |
| MX (1) | MX2023001883A (https=) |
| PE (1) | PE20231318A1 (https=) |
| TW (1) | TW202227431A (https=) |
| WO (1) | WO2022040293A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022140325A1 (en) * | 2020-12-22 | 2022-06-30 | Gilead Sciences, Inc. | 6-substituted indole compounds |
| TWI838670B (zh) * | 2020-12-22 | 2024-04-11 | 美商基利科學股份有限公司 | 經取代之吲哚化合物 |
| CR20230478A (es) | 2021-04-16 | 2023-11-30 | Gilead Sciences Inc | Compuestos de tienopirrol. |
| KR20240056747A (ko) | 2021-09-10 | 2024-04-30 | 길리애드 사이언시즈, 인코포레이티드 | 티에노피롤 화합물 |
| MX2024009441A (es) * | 2022-02-18 | 2024-08-14 | Bristol Myers Squibb Co | Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9). |
| WO2024102886A1 (en) * | 2022-11-10 | 2024-05-16 | Bristol-Myers Squibb Company | Substituted benzimidazole compounds useful as inhibitors of tlr9 |
| KR20250094727A (ko) * | 2022-11-10 | 2025-06-25 | 브리스톨-마이어스 스큅 컴퍼니 | Tlr9의 억제제로서 유용한 치환된 퀴놀론 화합물 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013092467A1 (en) * | 2011-12-20 | 2013-06-27 | F. Hoffmann-La Roche Ag | 7-azaindole inhibitors of crac |
| CN105992766A (zh) * | 2013-12-13 | 2016-10-05 | 武田药品工业株式会社 | 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物 |
| TW201630907A (zh) * | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| EA202091484A1 (ru) * | 2017-12-18 | 2021-03-25 | Бристол-Маерс Сквибб Компани | 4-азаиндольные соединения |
| JP7304352B2 (ja) * | 2017-12-19 | 2023-07-06 | ブリストル－マイヤーズ スクイブ カンパニー | ６－アザインドール化合物 |
| KR102730859B1 (ko) * | 2017-12-20 | 2024-11-15 | 브리스톨-마이어스 스큅 컴퍼니 | 아릴 및 헤테로아릴 치환된 인돌 화합물 |
-
2021
- 2021-08-18 WO PCT/US2021/046475 patent/WO2022040293A1/en not_active Ceased
- 2021-08-18 PE PE2023000276A patent/PE20231318A1/es unknown
- 2021-08-18 BR BR112023002662A patent/BR112023002662A2/pt unknown
- 2021-08-18 KR KR1020237009018A patent/KR20230052930A/ko active Pending
- 2021-08-18 JP JP2023512161A patent/JP2023539136A/ja active Pending
- 2021-08-18 MX MX2023001883A patent/MX2023001883A/es unknown
- 2021-08-18 TW TW110130426A patent/TW202227431A/zh unknown
- 2021-08-18 US US18/042,018 patent/US20230322770A1/en active Pending
- 2021-08-18 AR ARP210102328A patent/AR123284A1/es not_active Application Discontinuation
- 2021-08-18 AU AU2021328362A patent/AU2021328362A1/en not_active Abandoned
- 2021-08-18 CA CA3189816A patent/CA3189816A1/en active Pending
- 2021-08-18 EP EP21769573.3A patent/EP4200015B1/en active Active
- 2021-08-18 CN CN202180050343.7A patent/CN115956077A/zh active Pending
- 2021-08-18 IL IL300696A patent/IL300696A/en unknown
-
2023
- 2023-02-10 CL CL2023000428A patent/CL2023000428A1/es unknown
- 2023-02-15 CO CONC2023/0001670A patent/CO2023001670A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4200015B1 (en) | 2026-04-29 |
| KR20230052930A (ko) | 2023-04-20 |
| AU2021328362A1 (en) | 2023-03-23 |
| PE20231318A1 (es) | 2023-08-24 |
| WO2022040293A1 (en) | 2022-02-24 |
| CO2023001670A2 (es) | 2023-02-27 |
| JP2023539136A (ja) | 2023-09-13 |
| CN115956077A (zh) | 2023-04-11 |
| MX2023001883A (es) | 2023-03-10 |
| IL300696A (en) | 2023-04-01 |
| US20230322770A1 (en) | 2023-10-12 |
| EP4200015A1 (en) | 2023-06-28 |
| CL2023000428A1 (es) | 2023-07-28 |
| TW202227431A (zh) | 2022-07-16 |
| AR123284A1 (es) | 2022-11-16 |
| CA3189816A1 (en) | 2022-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023002662A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 | |
| BR112023002646A2 (pt) | Compostos de heteroarila substituída úteis como inibidores de tlr9 | |
| SA522431915B1 (ar) | Prmt5 مثبطات mta تعاونية مع | |
| BR112022007783A2 (pt) | Composto, composição farmacêutica, e, métodos para inibir proteína g12c de kras e para tratar câncer | |
| BR112021022624A2 (pt) | Compostos para o tratamento da doença de huntington | |
| ZA202100208B (en) | Heterocyclic and heteroaryl compounds for treating huntington's disease | |
| MX2023001917A (es) | Inhibidores de la fosfatasa shp2 y metodos para su uso. | |
| BR112019002610A2 (pt) | piridopirimidinonas inibidoras de cdk2/4/6 | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| BR112012022125A2 (pt) | composto, sal de dicloridrato, composição farmacêutica, uso do composto, e, método para tratar um paciente | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112017022349A2 (pt) | ?composto, composição, método, e, método para inibir uma proteína irak? | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| BR112019007108A2 (pt) | misturas herbicidas | |
| BR112023003580A2 (pt) | Compostos heterocíclicos | |
| BR112017019995A2 (pt) | composto, composição, mistura herbicida e método de controle do crescimento de vegetação | |
| MX2022011601A (es) | Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer. | |
| BR112022005472A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl), seus usos, processo de fabricação e composição farmacêutica | |
| BRPI0607302A2 (pt) | aminoácidos n-halogenados, aminoácidos n, n-dihalogenados e derivados, composição farmacêutica e estabilizada, método para controlar ou prevenir o crescimento de bactérias, micróbios, esporos, fungos ou vìrus ou a proliferação de infecções e da fonte de infecções e uso dos referidos compostos | |
| BR112023000588A2 (pt) | Derivados de piridazina como inibidores de alk5 e/ou alk4 | |
| BR112023020410A2 (pt) | Compostos de oxoisoindolina substituída por piridinila para tratamento de câncer | |
| BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
| PH12021551304A1 (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| BR112022000936A2 (pt) | Inibidores de enzimas |